会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Screen assembly and rear-projection type graphic display device
    • 屏幕组合和背投式图形显示装置
    • US20100165303A1
    • 2010-07-01
    • US12654287
    • 2009-12-16
    • Toshitaka MurataRyusaku TakahashiMasahiko MiyakeManabu KobayashiTakatsugu AizakiHironobu Fukutomi
    • Toshitaka MurataRyusaku TakahashiMasahiko MiyakeManabu KobayashiTakatsugu AizakiHironobu Fukutomi
    • G03B21/62G03B21/10
    • G03B21/10G03B21/62
    • A screen assembly and a rear-projection type graphic display device are provided to block overscanned light Lo projected outside a fresnel lens screen. The screen assembly 20A includes the fresnel lens screen 21, a screen retainer 22 and a light blocking member 23. The fresnel lens screen 21 forms an image on the side of a front surface 21b by image light Le incoming through a back surface 21a. The screen retainer 22 has a back surface 22a whose area is larger than the back surface 21a and the front surface 21b and which is opposed to the front surface 21b to hold it, and a front surface 22b located on opposite side of the back surface 22a to allow an image formed by the image light incoming through the back surface 21a to be visible through the front surface 22b. The screen retainer 22 has an optical transparency. The light blocking member 23 is arranged so as to surround respective side surfaces of the screen 21 in the form of a frame. At least part of the light blocking member 23 is arranged so as to project to the side of the back surface 21a of the screen.
    • 提供了屏幕组件和背投式图形显示装置,以阻挡投射在菲涅尔透镜屏幕外部的过扫描光线Lo。 屏幕组件20A包括菲涅尔透镜屏幕21,屏幕保持器22和遮光构件23.菲涅尔透镜屏幕21通过背面21a进入的图像光Le形成在前表面21b侧的图像。 屏幕保持器22具有面积大于后表面21a和前表面21b并且与前表面21b相对以保持它的后表面22a,并且位于背表面22a的相对侧上的前表面22b 以允许通过后表面21a进入的图像光形成的图像通过前表面22b可见。 屏幕保持器22具有光学透明度。 遮光构件23被布置成围绕框架的形式的屏幕21的各个侧表面。 遮光构件23的至少一部分配置成向屏幕的背面21a侧突出。
    • 2. 发明授权
    • Screen assembly and rear-projection type graphic display device
    • 屏幕组合和背投式图形显示装置
    • US08388147B2
    • 2013-03-05
    • US12654287
    • 2009-12-16
    • Toshitaka MurataRyusaku TakahashiMasahiko MiyakeManabu KobayashiTakatsugu AizakiHironobu Fukutomi
    • Toshitaka MurataRyusaku TakahashiMasahiko MiyakeManabu KobayashiTakatsugu AizakiHironobu Fukutomi
    • G03B21/14
    • G03B21/10G03B21/62
    • A screen assembly and a rear-projection type graphic display device are provided to block overscanned light Lo projected outside a fresnel lens screen. The screen assembly 20A includes the fresnel lens screen 21, a screen retainer 22 and a light blocking member 23. The fresnel lens screen 21 forms an image on the side of a front surface 21b by image light Le incoming through a back surface 21a. The screen retainer 22 has a back surface 22a whose area is larger than the back surface 21a and the front surface 21b and which is opposed to the front surface 21b to hold it, and a front surface 22b located on opposite side of the back surface 22a to allow an image formed by the image light incoming through the back surface 21a to be visible through the front surface 22b. The screen retainer 22 has an optical transparency. The light blocking member 23 is arranged so as to surround respective side surfaces of the screen 21 in the form of a frame. At least part of the light blocking member 23 is arranged so as to project to the side of the back surface 21a of the screen.
    • 提供了屏幕组件和背投式图形显示装置,以阻挡投射在菲涅尔透镜屏幕外部的过扫描光线Lo。 屏幕组件20A包括菲涅尔透镜屏幕21,屏幕保持器22和遮光构件23.菲涅耳透镜屏幕21通过背面21a进入的图像光Le形成在前表面21b侧的图像。 屏幕保持器22具有面积大于后表面21a和前表面21b并且与前表面21b相对以保持它的后表面22a,并且位于背表面22a的相对侧上的前表面22b 以允许通过后表面21a进入的图像光形成的图像通过前表面22b可见。 屏幕保持器22具有光学透明度。 遮光构件23被布置成围绕框架的形式的屏幕21的各个侧表面。 遮光构件23的至少一部分配置成向屏幕的背面21a侧突出。
    • 7. 发明授权
    • High-molecular weight conjugate of steroids
    • 类固醇的高分子量缀合物
    • US08703878B2
    • 2014-04-22
    • US12678620
    • 2008-09-26
    • Masayuki KitagawaToshitaka Murata
    • Masayuki KitagawaToshitaka Murata
    • A61K47/48
    • A61K31/785A61K47/60A61K47/645
    • Enzymes in the body vary among different species, and also vary among individuals of the same species. Thus, it has been demanded to develop a novel steroid-containing pharmaceutical preparation which can release a drug in a manner independent of the enzymes present in the body, and which is expected to have an efficacious therapeutic effect.Disclosed is a high-molecular weight conjugate of a steroid, comprising a structure in which a carboxylic acid group of a polymer having a polyethylene glycol moiety and a succinic acid monoamide moiety having two or more succinic acid monoamide units is ester-bonded to a hydroxy group in the steroid.
    • 身体中的酶在不同的物种中不同,并且在同一物种的个体中也是不同的。 因此,已经要求开发一种能够以与体内存在的酶无关的方式释放药物的新型类固醇药物制剂,其预期具有有效的治疗效果。 公开了类固醇的高分子量缀合物,其包含其中具有聚乙二醇部分的聚合物的羧酸基团和具有两个或多个琥珀酸单酰胺单元的琥珀酸单酰胺部分与羟基酯键合的结构 在类固醇组。
    • 10. 发明申请
    • Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer
    • 含微水溶性抗癌剂和新型嵌段共聚物的胶束制剂
    • US20090156742A1
    • 2009-06-18
    • US12322322
    • 2009-01-30
    • Kazuhisa ShimizuToshitaka MurataKatsuhiko Sagawa
    • Kazuhisa ShimizuToshitaka MurataKatsuhiko Sagawa
    • C08L53/00
    • A61K9/1075A61K31/337A61K47/42
    • A novel micellar preparation in which the solubility of a sparingly water-soluble anticancer agent has been heightened and which after intravenous administration, enables a high blood concentration to be maintained. The preparation has high medicinal activity and/or is reduced in side effects. The micellar preparation is formed from a block copolymer represented by the following general formula (1): [wherein R1 represents hydrogen or C1-5 alkyl; R2 represents C1-5 alkylene; R3 represents methylene or ethylene; R4 represents hydrogen or C1-4 acyl; R5 represents hydroxyl, optionally substituted aryl C2-8 alkoxyl, substituted C1-4 alkylamino, or amino having a residue of either an amino acid or a peptide derivative; n is an integer of 5 to 1,000; m is an integer of 2 to 300; and x is an integer of 1 to 300; provided that the proportion of hydroxy in the R5's is 0 to 99% and x is not larger than m] and a sparingly water-soluble anticancer agent.
    • 提高了微水溶性抗癌剂的溶解性的新型胶束制剂,并且在静脉内给药后能够维持高血药浓度。 该制剂具有高药用活性和/或副作用减少。 胶束制剂由下列通式(1)表示的嵌段共聚物形成:[其中R 1表示氢或C 1-5烷基; R2表示C1-5亚烷基; R3表示亚甲基或亚乙基; R4代表氢或C1-4酰基; R5表示羟基,任选取代的芳基C2-8烷氧基,取代的C1-4烷基氨基或具有氨基酸或肽衍生物残基的氨基; n为5〜1000的整数。 m为2〜300的整数, x为1〜300的整数。 条件是R5中羟基的比例为0-99%且x不大于m]和少量水溶性抗癌剂。